For transplant patients under the care of Dr. Moreb, you are 3.6 times more likely to survive 2 years and 1.7 times more likely to survive 4 years, as compared to the average SEER facility. They have provided their transplant experience and report a 2 year survival rate of 90%* versus the SEER data of 64.1%, and a 4 year survival rate of 70%* versus the SEER survival rate of 49.2%. The data presented by Dr. Moreb is from first transplant and as a result will be understated by 3 to 5 percent from where they would be if they provided data from the time of diagnosis. Dr. Moreb's survival is therefore slightly better than is represented here. Receiving care through Dr. Moreb at Shands at the University of Florida provides another excellent facility for patients in the Southern Region.
Jan S. Moreb MD, Short Biosketch:
Professor Bone Marrow Transplant Program, University of Florida, Department of Medicine.
Dr Moreb is a physician scientist who maintains basic and clinical research expertise. He is board certified in Internal Medicine and Hematology. He is well published with a focus on multiple myeloma and stem cell transplantation. He is a member of many medical societies including the American Society of Hematology, the American Association for Cancer Research, and the American Society for Blood and Marrow Transplantation.
MD - Hebrew University Hadassah Medical School, Jerusalem, Israel
Internship - Hadassah University Hospital, Jerusalem, Israel
Hematology Residency - Hadassah University Hospital, Jerusalem, Israel
Resident and Chief Resident(Internal Medicine) - Shaare-Zedek University Hospital, Jerusalem, Israel
Oncology Hematology Fellowship - University of Florida, College of Medicine, Gainesville, Florida
His areas of specialization in the laboratory research are in drug resistance, gene expression, and cell biology. His research interests and activities have involved laboratory research focused on aldehyde dehydrogenases (ALDH) isozymes and their role in drug resistance of hematopoietic stem cells (HSC) as well as cancer cells and more recently as a possible marker for lung cancer stem cell.
In addition, he is active in different clinical research projects. These involve different aspects of stem cell transplantation (SCT) including stem cell mobilization, engraftment, and the use of new methods to improve outcomes after autologous SCT (ASCT) for myeloma. Tandem transplants, post-transplant maintenance therapy, including adoptive immunotherapy and Phase I-III for Multiple Myeloma are his current areas of interest.
Dr Moreb has focused his efforts on taking care of patients with multiple myeloma in addition to other hematologic malignancies. He has gained the respect of his peers from around the country and the reputation as one of the experts on multiple myeloma and other related monoclonal gammopathies.